Clinical Trial Update: Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) [Phase 2]

View source ↗

Summary

Phase 2 NEOTORCH-BREAST02 trial is evaluating neoadjuvant chemotherapy with toripalimab in triple-negative breast cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: TNBC, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING